Nov 22 (Reuters) - The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer's blockbuster Vyndaqel.

The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins accumulate in the heart and can cause the organ to fail.

(Reporting by Chandni Shah, Mariam Sunny and Bhanvi Satija in Bengaluru; Editing by Shilpi Majumdar and Sandra Maler)

((Mariam.ESunny@thomsonreuters.com;))